medigraphic.com
ISSN 1560-4381 (Print)

2021, Number 2

<< Back Next >>

Correo Científico Médico 2021; 25 (2)

Antiphospholipid syndrome: a clinical case

Vila BJA, Solís PQ, Rojas MMA, Ricardo LA, Serrano GR

Language: Spanish
References: 13
Page:
PDF size: 217.37 Kb.


ABSTRACT

Antiphospholipid syndrome is a systemic autoinmune disease characterized by the appearance of recurrent thrombotic events, fetal loss, and high levels of antiphospholipid antibodies. A 29-year-old female patient came to the hospital with a history of immune thrombocytopenic purpura, fetal death and neurological disease of recent onset due to headache, deviation of the labial commissure to the right, dysarthria and progressive motor deficit, which is lateralized to a hemibody. The patient was diagnosed with a secondary antiphospholipid syndrome with multiple focal thrombosis of the distal territory from the right middle brain artery. The treatment was based on anticoagulation with sodium heparin, platelet antiaggregation and systemic steroids, supplemented with physical therapy and rehabilitation measures. The evolutionary response to the therapy was adequate, overcoming the condition with partial recovery of motor functions at "Dr. Salvador Allende" High Technology Medical Center, located in Chuao, Baruta municipality, Caracas, Venezuela.


REFERENCES

  1. Nahas O, Serhal L, Germanos M, Abou N, Maalouly G, Haddad F, et al. Syndrome des antiphospholipides: À propos de 30 cas. J Med Liban. 2016[citado 29/06/2019]; 64 (2): 78-83. Disponible en: http://www.lebanesemedicaljournal.org/articles/64-2/original3.pdf

  2. Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, et al. Mortality in the catastrophic antiphospholipid syndrome. Causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006[citado 29/06/ 2019]; 54(8):2568–76.Disponible en : https://onlinelibrary.wiley.com/doi/full/10.1002/art.22018

  3. Cervera R. Estrategias Terapéuticas en el Síndrome Antifosfolípido. Reumatol Clín. 2010[citado 29/06/2019]; 6(1): 37- 42. Disponible en: https://www.reumatologiaclinica.org/es-estrategias-terapeuticas-el-sindrome-antifosfolipidico-articulo-S1699258X09001004

  4. Correa A, Valderrama O, Angel R, Sáez J, Villablanca E. Síndrome antifosfolipidos y embarazo. Rev Chil Obstet Ginecol. 2002 [citado 29/06/2019]; 67(3): 196-202. Disponible en: https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0717-75262002000300005

  5. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992[citado 29/06/2019]; 117(12); 997-1002.Disponible en: https://www.acpjournals.org/doi/abs/10.7326/0003-4819-117-12-997

  6. Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A, et al. Endothelial activation by: a potencial pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun. 2000[citado 29/06/2019]; 15(2):237-240.Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0896841100904128

  7. Hörkkö S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NF, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest. 1996[citado 29/06/2019]; 98(3):815-825.Disponible en: https://www.jci.org/articles/view/118854/pdf

  8. 8.Tincani A, Balestrieri G, Allegri F, Cinquini M, Vianelli M, Koike T, et al. Overview on anticardiolipin ELISA standardization. J Autoimmun. 2000[citado 29/06/2019]; 15(2):195-197. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0896841100903998

  9. Levine JS, Subang R, Koh JS, Rauch J. Induction of anti-phospholipid autoantibodies by B2-glycoprotein I bound to apoptotic thymocytes. J Autoimmun. 1998[citado 29/06/2019]; 11(5): 413-424. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0896841198902359

  10. Hady E, Vincent C, Pascale M, Philippe D, Guillaume L, Pierre Emmanuel B, et al. Recurrent pregnancy loss: current perspectives. Int J Womens Health. 2017[citado 29 /06/2019];9: 331-345.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440030/

  11. Jara LJ, Medina G, Cruz Cruz P, Olivares-Rivera J, Duarte-Salazar C, Saavedra MA. Non Criteria or Seronegative Obstetric Antiphospholipid Syndrome? Isr Med Assoc J. 2017[citado 29/06/2019];19(6):382-386.Disponible en: https://www.ima.org.il/MedicineIMAJ/viewarticle.aspx?aid=4123

  12. El Hachem H, Crepaux V, May-Panloup P, Descamps P, Legendre G, Bouet PE. Recurrent pregnancy loss: current perspectives. Int J Womens Health. 2017[citado 29/06/2019];9:331-345. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440030/

  13. Sciascia S, Baldovino S, Schreiber K, Solfietti L, Radin M, Cuadrado MJ, et al. Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. Clin Mol Allergy. 2016[citado 29/06/2019]; 14:6.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947367/




2020     |     www.medigraphic.com